Heinz-Josef Lenz, MD
Medical Oncology · Los Angeles, CANPI 1700814209
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $119,126 of the $185,202 with a category attached, or 64.3%. 20 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 29.6% of the total. 2025 is the largest year on record at $81,732, 3.2 times the $25,900 reported in 2019. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $1226.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$55K
- Merck$34K
- Bayer$29K
- Biontech SE$15K
- EMD Serono Research & Development Institute, Inc.$15K
- AbbVie$11K
- plus $27K from 14 others
Across 520 payments — averaging $21,902 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.5M
- E.r. Squibb & Sons, L.L.C.$2.2M
- Pfizer$1.5M
- G1 Therapeutics, Inc.$628K
- Boehringer Ingelheim$573K
- Takeda Pharmaceuticals U.S.A., Inc.$480K
- plus $1.5M from 27 others
What the payments were for
- Consulting fees$119,12664%
- Speaking & faculty fees$6,4043%
- Travel & lodging$52,44828%
- Food & beverage$2,0181%
- Education$5,2063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 56 | $54,779 |
| Merck | 11 | $33,744 |
| Bayer | 27 | $29,081 |
| Biontech SE | 7 | $14,754 |
| EMD Serono Research & Development Institute, Inc. | 2 | $14,593 |
| AbbVie | 15 | $10,995 |
| GSK | 6 | $5,373 |
| G1 Therapeutics, Inc. | 3 | $4,222 |
| Boehringer Ingelheim International GmbH | 4 | $3,119 |
| Jazz Pharmaceuticals Inc. | 1 | $2,750 |
| Partner Therapeutics, Inc. | 7 | $2,549 |
| Merck Kgaa | 1 | $2,000 |
| Veloxis Pharmaceuticals, Inc. | 2 | $2,000 |
| Astellas Pharma US Inc | 1 | $1,875 |
| Beigene USA, Inc. | 1 | $1,500 |
| Daiichi Sankyo Inc. | 2 | $1,278 |
| Amgen | 2 | $520 |
| AstraZeneca | 1 | $27 |
| Sobi, Inc | 1 | $26 |
| Eisai Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,202 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.